ijms-logo

Journal Browser

Journal Browser

New Research Progresses on Multifaceted Cholinergic Signaling

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: closed (20 September 2025) | Viewed by 1211

Special Issue Editor


E-Mail Website
Guest Editor
Division of Clinical Geriatrics, Centre for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, NEO, Seventh Floor, 141 52 Stockholm, Sweden
Interests: dementia; Alzheimer's disease (AD); neuromotor disorders; amyotrophic lateral sclerosis (ALS); neuronal and non-neuronal cholinergic signaling

Special Issue Information

Dear Colleagues,

The cholinergic signaling system is widespread throughout the body. Cholinergic cells are defined by intracellular expression of the acetylcholine-biosynthesizing enzyme, ChAT, i.e., the explicit marker of cholinergic cells and neurons.

There are two main types of cholinergic cells: neuronal and non-neuronal cells. The neuronal cholinergic system consists of three subnetworks. (1) the central cholinergic system originating from basal forebrain projecting extensively and directly throughout the brain. (2) the parasympathetic system that originates from 12 cranial nerves (CN I-XII), projecting to various organs, tissues, and glands in the body and thereby controlling the function of diverse organs, muscles, and glands. (3) the cholinergic circuitry in the enteric nervous system, where about 64% of neurons are cholinergic, involving sensory and vascular reflexes and controlling motility (muscular) and secretory (mucosal) reflexes within the gastrointestinal tracts. The non-neuronal cholinergic system consists of numerous non-excitable ChAT-positive cells. An example is lymphocytes/spleenocytes forming a so-called cholinergic anti-inflammatory system. Another is the spermic cholinergic system that is involved in sperm motility and capacitation.

Thus, it is hardly surprising that malfunctioning or degeneration of the cholinergic systems can be involved in many disorders. For instance, early degeneration of the central cholinergic neurons is one of the hallmarks of Alzheimer's disease, dementia with Lewy body (including Parkinson’s dementia), and Down’s syndrome. Cholinergic interneurons in the striatum, which target the nigrostriatal system, are affected in Parkinson’s disease, in corticobasal degeneration syndrome, and in progressive supranuclear palsy. Early and progressive cholinergic neurodegeneration occurs also in motor neuron disorders, which are characterized by progressive muscle weakness. A particularly devastating example is amyotrophic lateral sclerosis (ALS), which selectively affects the cholinergic motor neurons in the cortex and spinal cord, as well as various cranial nerves. An age-dependent decline in the efficiency of the cholinergic anti-inflammatory system in the elderly might explain why COVID-19 infection induced a more severe cytokine storm, which was associated with poor prognosis in the elderly population.

Despite all these, basic research on cholinergic systems is currently scarce, perhaps due to the illusion that we already know all about this system! Yet now and then come new insights that put this illusion into question.

In this Special Issue we are calling for new insights and advances about the function of the crucial and multifaceted cholinergic signaling. This Special Issue will consider both original articles, reviews as well as new hypotheses. We are calling for articles in the whole spectrum of the cholinergic signaling system! We, particularly, encourage submission of research papers investigating the intracellular cholinergic signaling and its association with mitochondrial function and the role of cholinergic signaling in resistance, survival, and recolonization of tumor cells following diverse cancer therapy. In addition, we look forward to research papers describing new robust and reliable methodological approaches in, for instance, measuring the function of ChAT, the key cholinergic enzyme, or levels of acetylcholine in biological fluids, which are crucial for developing novel research approaches and for monitoring changes in the cholinergic signaling upon therapeutic strategies that directly or indirectly may be able to restore the neuronal and non-neuronal cholinergic function or prevent further deterioration of the cholinergic system.

Dr. Taher Darreh-Shori
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cholinergic signaling
  • choline acetyltransferase (ChAT)
  • nicotinic acetylcholine receptors (AChRs)
  • muscarinic acetylcholine receptors (mAChRs)
  • mitochondrial acetylcholine receptors
  • cholinergic anti-inflammatory pathway
  • cholinergic signaling in cancer
  • cholinergic signaling in mitochondria
  • cholinergic signaling in ALS
  • cholinergic signaling in dementia
  • cholinergic signaling in COVID-19

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

22 pages, 7453 KB  
Article
Comparative Analysis of Cholinergic Machinery in Carcinomas: Discovery of Membrane-Tethered ChAT as Evidence for Surface-Based ACh Synthesis in Neuroblastoma Cells
by Banita Thakur, Samar Tarazi, Lada Doležalová, Homira Behbahani and Taher Darreh-Shori
Int. J. Mol. Sci. 2025, 26(21), 10311; https://doi.org/10.3390/ijms262110311 - 23 Oct 2025
Abstract
The cholinergic system is one of the most ancient and widespread signaling systems in the body, implicated in a range of pathological conditions—from neurodegenerative disorders to cancer. Given its broad relevance, there is growing interest in characterizing this system across diverse cellular models [...] Read more.
The cholinergic system is one of the most ancient and widespread signaling systems in the body, implicated in a range of pathological conditions—from neurodegenerative disorders to cancer. Given its broad relevance, there is growing interest in characterizing this system across diverse cellular models to enable drug screening, mechanistic studies, and exploration of new therapeutic avenues. In this study, we investigated four cancer cell lines: one of neuroblastoma origin previously used in cholinergic signaling studies (SH-SY5Y), one non-small cell lung adenocarcinoma line (A549), and two small cell lung carcinoma lines (H69 and H82). We assessed the expression and localization of key components of the cholinergic system, along with the cellular capacity for acetylcholine (ACh) synthesis and release. Whole-cell flow cytometry following membrane permeabilization revealed that all cell lines expressed the ACh-synthesizing enzyme choline acetyltransferase (ChAT). HPLC-MS analysis confirmed that ChAT was functionally active, as all cell lines synthesized and released ACh into the conditioned media, suggesting the presence of autocrine and/or paracrine ACh signaling circuits, consistent with previous reports. The cell lines also demonstrated choline uptake, indicative of functional choline and/or organic cation transporters. Additionally, all lines expressed the ACh-degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), as well as the alfa seven (α7) nicotinic and M1 muscarinic ACh receptor subtypes. Notably, flow cytometry of intact SH-SY5Y cells revealed two novel findings: (1) ChAT was localized to the extracellular membrane, a feature not observed in the lung cancer cell lines, and (2) BChE, rather than AChE, was the predominant membrane-bound ACh-degrading enzyme. These results were corroborated by both whole-cell and surface-confocal microscopy. In conclusion, our findings suggest that a functional cholinergic phenotype is a shared feature of several carcinoma cell lines, potentially serving as a survival checkpoint that could be therapeutically explored. The discovery of extracellular membrane-bound ChAT uniquely in neuroblastoma SH-SY5Y cells points to a novel form of in situ ACh signaling that warrants further investigation. Full article
(This article belongs to the Special Issue New Research Progresses on Multifaceted Cholinergic Signaling)
Show Figures

Figure 1

13 pages, 1098 KB  
Article
The Human Alpha3 Beta2 Neuronal Nicotinic Acetylcholine Receptor Can Form Two Distinguishable Subtypes
by Doris C. Jackson, Marcel K. Hall and Sterling N. Sudweeks
Int. J. Mol. Sci. 2025, 26(19), 9506; https://doi.org/10.3390/ijms26199506 - 28 Sep 2025
Viewed by 374
Abstract
Diverse neuronal nicotinic acetylcholine receptor (nAChR) subtypes are expressed in hippocampal interneurons. Single-cell analysis of mRNA expression previously revealed prominent co-expression of the α3 and β2 subunits within rat interneurons in the CA1 region. Although the α3 subunit (traditionally expressed together with β4) [...] Read more.
Diverse neuronal nicotinic acetylcholine receptor (nAChR) subtypes are expressed in hippocampal interneurons. Single-cell analysis of mRNA expression previously revealed prominent co-expression of the α3 and β2 subunits within rat interneurons in the CA1 region. Although the α3 subunit (traditionally expressed together with β4) is usually associated with the peripheral nervous system, its significant co-expression with the β2 subunit in hippocampal interneurons suggests a distinct, potentially novel central nervous system nAChR subtype. We demonstrate that the human α3 and β2 subunits injected into Xenopus laevis oocytes can assemble into at least two functionally distinct subtypes of nAChRs based on different subunit stoichiometries. These subtypes exhibit similar reversal potentials but differ significantly in their desensitization kinetics and acetylcholine (ACh) affinities. The response obtained from a 1:5 α3:β2 mRNA injection ratio shows a higher affinity for ACh and significantly greater desensitization during prolonged ACh application compared to the response obtained from a 5:1 α3:β2 mRNA injection ratio. The identification of distinct functional α3β2 subtypes, characterized by differential desensitization kinetics and ACh affinity, could represent novel targets for the potential development of highly selective cognitive therapeutics for conditions such as Alzheimer’s disease, autism spectrum disorder, and attention deficit hyperactivity disorder, where hippocampal nAChRs are implicated. Full article
(This article belongs to the Special Issue New Research Progresses on Multifaceted Cholinergic Signaling)
Show Figures

Figure 1

Back to TopTop